Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Cell
|
September 24, 2016
Lifting the Differentiation Embargo
Anne-Louise Latif, Tessa L Holyoake
Medical Mycology Case Reports
|
December 28, 2013
Splenectomy as an effective debulking therapy for disseminated mould infection in acute myeloid leukaemia following adjuvant therapy with interferon gamma and liposomal amphotericin
Anne-Louise Latif, Chrsitina Harper, Ian Macdonald, et al.
Leukemia Research Reports
|
December 28, 2013
Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience
Anne-Louise Latif, Grant McQuaker, Anne Parker, et al.
Journal of Clinical Apheresis
|
December 30, 2020
Implications of CAR-T cell therapy on apheresis services: a Scottish perspective
Gillian A Horne, Jennifer Laird, Anne Louise Latif, et al.
British Journal of Anaesthesia
|
March 23, 2024
Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK
Tasneem Pirani, Anthony Wilson, David Brealey, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 8, 2020
A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency
Sarah K Westbury, Claire S Whyte, Jonathan Stephens, et al.
Blood Advances
|
September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian Brodermann, et al.
Nature Communications
|
January 12, 2021
BRD4-mediated repression of p53 is a target for combination therapy in AML
Anne-Louise Latif, Ashley Newcombe, Sha Li, et al.
Blood
|
August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing S Tiong, Jenny O'Nions, et al.
Hemasphere
|
May 22, 2024
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
Gloria Iacoboni, Josu Iraola-Truchuelo, Maeve O'Reilly, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Cell
|
September 24, 2016
Lifting the Differentiation Embargo
Anne-Louise Latif, Tessa L Holyoake
Medical Mycology Case Reports
|
December 28, 2013
Splenectomy as an effective debulking therapy for disseminated mould infection in acute myeloid leukaemia following adjuvant therapy with interferon gamma and liposomal amphotericin
Anne-Louise Latif, Chrsitina Harper, Ian Macdonald, et al.
Leukemia Research Reports
|
December 28, 2013
Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience
Anne-Louise Latif, Grant McQuaker, Anne Parker, et al.
Journal of Clinical Apheresis
|
December 30, 2020
Implications of CAR-T cell therapy on apheresis services: a Scottish perspective
Gillian A Horne, Jennifer Laird, Anne Louise Latif, et al.
British Journal of Anaesthesia
|
March 23, 2024
Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK
Tasneem Pirani, Anthony Wilson, David Brealey, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 8, 2020
A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency
Sarah K Westbury, Claire S Whyte, Jonathan Stephens, et al.
Blood Advances
|
September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian Brodermann, et al.
Nature Communications
|
January 12, 2021
BRD4-mediated repression of p53 is a target for combination therapy in AML
Anne-Louise Latif, Ashley Newcombe, Sha Li, et al.
Blood
|
August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing S Tiong, Jenny O'Nions, et al.
Hemasphere
|
May 22, 2024
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
Gloria Iacoboni, Josu Iraola-Truchuelo, Maeve O'Reilly, et al.
Page
of 2